Screener
AnaptysBio, Inc. ANAB Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by AnaptysBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: AnaptysBio, Inc.’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:20 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219515
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Net loss | $(52,884) | $(39,329) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 130 | 146 |
| Stock-based compensation | 14,218 | 9,170 |
| Accretion/amortization of investments, net | (8) | (1,667) |
| Amortization of right-of-use assets – operating | 480 | 460 |
| Non-cash interest expense for sale of future royalties | 20,859 | 18,061 |
| Changes in operating assets and liabilities: |
Item 1. Consolidated Financial Statements
FAQ
- What is AnaptysBio, Inc.'s stock-based comp?
- AnaptysBio, Inc. (ANAB) reported stock-based comp of $14.22M in Q1 2026.
- How has AnaptysBio, Inc.'s stock-based comp changed year-over-year?
- AnaptysBio, Inc.'s stock-based comp increased by 55.0% year-over-year, from $9.17M to $14.22M.
- What is the long-term trend for AnaptysBio, Inc.'s stock-based comp?
- Over 4 years (2021 to 2025), AnaptysBio, Inc.'s stock-based comp has grown at a 23.8% compound annual growth rate (CAGR), from $15.35M to $36.07M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about AnaptysBio, Inc.'s stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude